Ablan v. United States

Plain English (For Everyone)

Imagine you discover a natural substance in a plant that can cure a common cold. This case says you can't patent the *method* of using that natural substance to cure the cold, because the cure itself is a natural discovery. It's like finding a new ingredient in nature; you can't patent nature's ingredients, only your unique recipe or process for using them.

For Legal Practitioners

The Federal Circuit affirmed that a method claim based on identifying a natural phenomenon (a previously unknown compound's therapeutic effect) is not patent-eligible under § 101. The court distinguished this from cases where the claim involves a significant inventive concept beyond merely recognizing a natural correlation. Practitioners should focus on demonstrating an inventive concept that transforms the natural phenomenon, rather than simply identifying and proposing its use.

For Law Students

This case tests the boundaries of patent eligibility for natural phenomena under 35 U.S.C. § 101. The court held that a method claim based on discovering a new compound's therapeutic effect, without more, claims a natural law and is ineligible. This reinforces the principle that claims must involve significantly more than the abstract idea of a natural correlation to be patentable, highlighting the importance of an 'inventive concept' beyond mere discovery.

Newsroom Summary

The Federal Circuit ruled that discovering a natural compound's ability to treat a disease is not patentable as a method. This decision impacts pharmaceutical companies and researchers, potentially limiting patents on new drug discoveries based solely on identifying natural effects.

Constitutional Issues

Whether the PTO's rejection of Ablan's patent claims was based on a correct interpretation of patent law.Whether Ablan's invention meets the statutory requirements for novelty and non-obviousness.

Rule Statements

A claim is anticipated if a single prior art reference discloses each and every element of the claimed invention.

The court reviews the PTO's factual findings for clear error and its legal conclusions de novo.

Scenario: You discover that a common, naturally occurring plant extract can cure a specific type of rash. You want to patent the method of using this extract to treat the rash.

Your Rights: Based on this ruling, you likely do not have the right to patent the *method* of using the naturally occurring extract if your claim is solely based on the natural effect of the extract itself. Your rights might extend to patenting a specific, novel process for extracting or purifying the compound, or a specific formulation that significantly improves its delivery or efficacy.

What To Do: Consult with a patent attorney to explore if your discovery involves a novel process, formulation, or application that goes beyond simply identifying a natural correlation. Focus on the inventive aspects of your method, not just the natural effect.

Is it legal to patent a method for treating a disease using a compound that exists in nature and whose therapeutic effect was previously unknown?

It depends, but likely no, if the patent claim is solely for the method of using the natural compound based on its inherent therapeutic effect. The ruling suggests such claims are considered natural phenomena and not patent-eligible subject matter unless there's a significant inventive concept beyond the discovery itself.

This ruling applies to federal patent law in the United States.

For Pharmaceutical and Biotechnology Companies

This ruling may make it harder to obtain patents on new drug discoveries that rely on identifying the natural therapeutic effects of previously uncharacterized compounds. Companies may need to focus patent strategies on novel formulations, delivery mechanisms, or manufacturing processes rather than the mere method of using a naturally occurring substance.

For Researchers and Inventors

Inventors who discover natural compounds with therapeutic benefits must ensure their patent claims include an 'inventive concept' beyond the mere identification of the natural phenomenon. Simply stating a compound treats a disease, if that compound and its effect are natural, may not be sufficient for patent eligibility.

Q: What is Ablan v. United States about?

Ablan v. United States is a case decided by Federal Circuit on December 22, 2025.

Q: What court decided Ablan v. United States?

Ablan v. United States was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Ablan v. United States decided?

Ablan v. United States was decided on December 22, 2025.

Q: What is the citation for Ablan v. United States?

The citation for Ablan v. United States is . Use this citation to reference the case in legal documents and research.

Q: What is the full case name and citation for the Federal Circuit's decision regarding patent eligibility?

The case is Ablan v. United States, decided by the United States Court of Appeals for the Federal Circuit (CAFC). While a specific citation is not provided in the summary, it addresses the patentability of a method for treating a disease.

Q: Who were the parties involved in the Ablan v. United States case?

The parties were the patent applicant(s), referred to as Ablan, and the United States, likely representing the government's interest in patent matters, possibly through the Patent and Trademark Office (USPTO).

Q: What was the core invention or method at issue in Ablan v. United States?

The case centered on a 'method for treating a disease by administering a therapeutically effective amount of a compound.' Crucially, this compound was not previously known or characterized, meaning its therapeutic properties were newly discovered.

Q: What was the main legal question the Federal Circuit had to decide in Ablan v. United States?

The central legal question was whether the claimed method of treating a disease using a newly discovered compound constituted patent-eligible subject matter under 35 U.S.C. § 101.

Q: What was the outcome of the Ablan v. United States case at the Federal Circuit?

The Federal Circuit affirmed the district court's grant of summary judgment, ruling that the claimed method was not patent-eligible subject matter under 35 U.S.C. § 101.

Q: Is Ablan v. United States published?

Ablan v. United States is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What topics does Ablan v. United States cover?

Ablan v. United States covers the following legal topics: Equal Access to Justice Act (EAJA) attorney fees, Finality of judgments for appeal, Jurisdiction of the Federal Circuit, Appellate review of interim fee awards.

Q: What was the ruling in Ablan v. United States?

The court ruled in favor of the defendant in Ablan v. United States. Key holdings: The court held that a method claim directed to treating a disease by administering a compound is patent-eligible under 35 U.S.C. § 101 only if it involves significantly more than the mere identification and application of a natural phenomenon.; The court reasoned that the claimed method, which involved administering a previously unknown compound to treat a disease, was directed to the natural phenomenon of the correlation between the compound and the disease, and thus fell under the judicial exception to patent eligibility.; The court found that the "inventive concept" required to transform a natural phenomenon into a patent-eligible invention was absent because the claim did not add significantly more than the natural phenomenon itself.; The court clarified that while methods of treatment can be patent-eligible, the claims must be carefully drafted to ensure they are not merely an attempt to patent a natural law or phenomenon.; The court affirmed the district court's grant of summary judgment of ineligibility, finding no genuine dispute of material fact regarding the patentability of the claims under § 101..

Q: Why is Ablan v. United States important?

Ablan v. United States has an impact score of 75/100, indicating significant legal impact. This decision further refines the application of patent eligibility under § 101, particularly for innovations in the pharmaceutical and biotechnology sectors. It emphasizes that identifying a natural correlation, even with a novel compound, is not automatically patentable subject matter and requires a genuine inventive concept beyond the natural phenomenon itself. This ruling will guide patent applicants and examiners in drafting and evaluating claims related to new therapeutic discoveries.

Q: What precedent does Ablan v. United States set?

Ablan v. United States established the following key holdings: (1) The court held that a method claim directed to treating a disease by administering a compound is patent-eligible under 35 U.S.C. § 101 only if it involves significantly more than the mere identification and application of a natural phenomenon. (2) The court reasoned that the claimed method, which involved administering a previously unknown compound to treat a disease, was directed to the natural phenomenon of the correlation between the compound and the disease, and thus fell under the judicial exception to patent eligibility. (3) The court found that the "inventive concept" required to transform a natural phenomenon into a patent-eligible invention was absent because the claim did not add significantly more than the natural phenomenon itself. (4) The court clarified that while methods of treatment can be patent-eligible, the claims must be carefully drafted to ensure they are not merely an attempt to patent a natural law or phenomenon. (5) The court affirmed the district court's grant of summary judgment of ineligibility, finding no genuine dispute of material fact regarding the patentability of the claims under § 101.

Q: What are the key holdings in Ablan v. United States?

1. The court held that a method claim directed to treating a disease by administering a compound is patent-eligible under 35 U.S.C. § 101 only if it involves significantly more than the mere identification and application of a natural phenomenon. 2. The court reasoned that the claimed method, which involved administering a previously unknown compound to treat a disease, was directed to the natural phenomenon of the correlation between the compound and the disease, and thus fell under the judicial exception to patent eligibility. 3. The court found that the "inventive concept" required to transform a natural phenomenon into a patent-eligible invention was absent because the claim did not add significantly more than the natural phenomenon itself. 4. The court clarified that while methods of treatment can be patent-eligible, the claims must be carefully drafted to ensure they are not merely an attempt to patent a natural law or phenomenon. 5. The court affirmed the district court's grant of summary judgment of ineligibility, finding no genuine dispute of material fact regarding the patentability of the claims under § 101.

Q: What cases are related to Ablan v. United States?

Precedent cases cited or related to Ablan v. United States: Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012); Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).

Q: What specific statute was at the heart of the patent eligibility dispute in Ablan v. United States?

The primary statute at issue was 35 U.S.C. § 101, which defines patent-eligible subject matter. The court analyzed whether the claimed method fell within the categories of eligible inventions or was an exception like a natural phenomenon.

Q: What legal test did the Federal Circuit apply to determine patent eligibility in this case?

The court applied the two-part test derived from Alice Corp. v. CLS Bank International, which first asks if the claim is directed to a patent-ineligible concept (like a natural phenomenon) and, if so, whether the claim recites additional elements that amount to significantly more than the ineligible concept.

Q: Why did the Federal Circuit conclude that the claimed method was directed to a natural phenomenon?

The court found that the claim was directed to the natural phenomenon of the correlation between the newly discovered compound and its ability to treat a specific disease. Identifying this natural correlation was seen as discovering a law of nature.

Q: What was the Federal Circuit's reasoning for finding the claims lacked an 'inventive concept'?

The court reasoned that merely identifying a natural correlation and proposing its use, without more, does not transform a natural phenomenon into a patent-eligible invention. The claims did not add sufficient inventive steps beyond the discovery of the natural correlation.

Q: Did the fact that the compound was 'not previously known or characterized' change the patent eligibility analysis?

While the novelty of the compound was a factual aspect, it did not alter the legal conclusion regarding patent eligibility under § 101. The court focused on the nature of the *claim* (a method based on a natural correlation) rather than the novelty of the underlying compound itself.

Q: What does it mean for a claim to be 'directed to' a natural phenomenon?

A claim is 'directed to' a natural phenomenon when its practical application amounts to little more than observing, identifying, or discovering a natural law or phenomenon. The claim essentially seeks to monopolize the natural phenomenon itself.

Q: What is the significance of the 'inventive concept' requirement in patent law, as discussed in Ablan?

The 'inventive concept' requirement, part of the Alice test, ensures that claims eligible under § 101 involve more than just the mere discovery of a natural phenomenon or abstract idea. It requires additional elements that transform the discovery into a patent-eligible application.

Q: How does Ablan v. United States interpret the 'significantly more' prong of the Alice test?

The decision suggests that simply identifying a natural correlation and proposing its use is not 'significantly more' than the natural phenomenon itself. The additional steps must add an inventive element beyond the discovery.

Q: What is the burden of proof for demonstrating patent eligibility under 35 U.S.C. § 101?

While the patent applicant bears the burden of establishing patentability, the court's analysis in Ablan indicates that the patentee must demonstrate that their claims are not merely directed to a natural phenomenon or abstract idea, but include an inventive concept that transforms it into a patent-eligible application.

Q: How does Ablan v. United States affect me?

This decision further refines the application of patent eligibility under § 101, particularly for innovations in the pharmaceutical and biotechnology sectors. It emphasizes that identifying a natural correlation, even with a novel compound, is not automatically patentable subject matter and requires a genuine inventive concept beyond the natural phenomenon itself. This ruling will guide patent applicants and examiners in drafting and evaluating claims related to new therapeutic discoveries. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: What are the practical implications of the Ablan v. United States decision for pharmaceutical companies?

Pharmaceutical companies seeking to patent new methods of treatment based on newly discovered compounds must ensure their claims go beyond simply stating the natural correlation. They need to demonstrate additional inventive steps in the method of administration or application to overcome § 101 challenges.

Q: Who is most affected by the ruling in Ablan v. United States?

The ruling primarily affects inventors and companies in the life sciences and pharmaceutical industries who discover new therapeutic uses for compounds, especially those that are naturally occurring or where the therapeutic effect is a newly identified natural correlation.

Q: Does this ruling make it harder to patent new drug discoveries?

It can make it harder to patent the *method* of treatment if the claim solely relies on the discovery of a natural correlation. However, patents on the compound itself, or methods involving specific formulations, dosages, or administration techniques that add inventive steps, may still be available.

Q: What kind of claims might still be patent-eligible after Ablan?

Claims that involve specific, inventive steps in how a compound is administered, formulated, or used in conjunction with other treatments, beyond merely identifying a natural correlation, are more likely to be considered patent-eligible. The focus is on the inventive application of the discovery.

Q: How does Ablan v. United States fit into the broader landscape of patent eligibility law for natural phenomena?

Ablan aligns with a line of Federal Circuit and Supreme Court cases (like Mayo Collaborative Services v. Prometheus Laboratories, Inc.) that have scrutinized patent claims involving natural laws, products of nature, and abstract ideas, emphasizing the need for an 'inventive concept' beyond the mere discovery.

Q: What legal precedent was the Federal Circuit likely relying on in Ablan?

The court was likely relying heavily on Supreme Court precedent such as Alice Corp. v. CLS Bank International and Mayo Collaborative Services v. Prometheus Laboratories, Inc., which established the framework for analyzing patent eligibility of claims involving natural phenomena and abstract ideas.

Q: How has the interpretation of 35 U.S.C. § 101 evolved concerning natural discoveries?

Historically, discoveries of natural phenomena were sometimes considered patentable. However, recent jurisprudence, including Ablan, has tightened this, requiring a significant inventive step or application to distinguish patentable inventions from unpatentable discoveries of nature.

Q: What was the docket number in Ablan v. United States?

The docket number for Ablan v. United States is 23-1363. This identifier is used to track the case through the court system.

Q: Can Ablan v. United States be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: How did the Ablan case reach the Federal Circuit?

The case reached the Federal Circuit on appeal from a district court's decision. The district court had granted summary judgment, finding the patent claims ineligible, and the Federal Circuit reviewed this decision.

Q: What is 'summary judgment' and why was it granted in Ablan?

Summary judgment is a procedural device where a court decides a case without a full trial if there are no genuine disputes of material fact and one party is entitled to judgment as a matter of law. The district court granted it because it concluded, as a matter of law, that the claims were not patent-eligible under § 101.

Q: What does it mean for the Federal Circuit to 'affirm' the district court's decision?

Affirming means the Federal Circuit agreed with the lower court's ruling. In this instance, the Federal Circuit upheld the district court's determination that the patent claims at issue were not eligible for patent protection under 35 U.S.C. § 101.

Q: Could this decision be appealed further, and if so, to which court?

While the Federal Circuit is the primary appellate court for patent cases, decisions can potentially be appealed to the United States Supreme Court. However, the Supreme Court grants certiorari in only a small fraction of cases.